期刊文献+

微小RNA-21对人乳腺癌细胞株紫杉醇耐药性的影响及其机制 被引量:12

Effects of miRNA-21 on paclitaxel-resistance in human breast cancer cells
下载PDF
导出
摘要 目的:探讨微小RNA-21(miR-21)对人乳腺癌细胞MCF-7和SKBR-3及其紫杉醇耐药株细胞生物学活性的影响。方法:体外研究采用紫杉醇逐步加量诱导法建立人乳腺癌细胞紫杉醇耐药株;通过观察细胞形态的变化和检测耐药基因MDRl、BCRP、MRPl的表达以鉴定耐药细胞株;检测MCF-7和SKBR-3亲本及耐药细胞中miR-21和凋亡相关基因Bax、Bcl-2的表达水平;用miR-21抑制剂和模拟物分别转染MCF-7和SKBR-3耐药和亲本细胞株,MrIT法和流式细胞术检测转染miR-21抑制剂后细胞对紫杉醇的敏感程度和细胞周期、凋亡的变化,并检测耐药基因和凋亡相关基因的表达。结果:成功建立人乳腺癌细胞紫杉醇耐药株MCF-7/PR和SKBR-3/PR,耐药细胞株中耐药基因MDRl、BCRP、MRPl表达均升高,抗凋亡基因Bcl-2升高,凋亡基因Bax下降,miR-21表达升高(P〈0.05);与对照组比较,miR-21抑制剂可提高耐药细胞株对紫杉醇的药物敏感性,增加细胞凋亡水平,增加细胞周期中G0/G1期细胞(P〈0.05),并可抑制耐药细胞株耐药基因的表达,降低Bcl-2/Bax比值(P〈0.05),而miR-21模拟物可刺激亲本细胞出现耐药细胞形态改变,并上调耐药基因的表达及Bcl-2/Bax比值(P〈0.05)。结论:乳腺癌紫杉醇耐药细胞株MCF-7/PR和SKBR.3/PR中miR-21表达上调;抑制miR-21表达可逆转人乳腺癌MCF-7/PR、SKBR-3/PR细胞株对紫杉醇化疗的耐药性。 Objective: To investigate the effects of miR-21 on paclitaxel-resistance in human breast cancer MCF-7/PR and SKBR-3/PR cells. Methods: Paclitaxel- resistant human breast cancer cell lines MCF-7/PR and SKBR-3/PR were established by stepwise selection in increasing concentration of paelitaxel. Cellular morphology, mRNA and protein level of MDR1, BCRP and MRP1 in MCF-7/PR and SKBR-3/PR ceils were determined. The expression of Bax, Bcl-2 and miR-21 in parental and paelitaxel-resistant cells was detected by RT-PCR and Western blotting. The synthetic miR-21 inhibitor or miR-21 mimic were transfected into MCF-7/PR, SKBR-3/PR and MCF-7, SKBR-3 ceils with Lipofectamine 2000. The miR-21 levels were determined by RT-PCR, and P-gp, Bcl-2 and Bax protein levels were examined by Western blotting. MTI" assay was used to measure the cell viability, and flow cytometry was performed to analyze the cell cycle and apoptosis. Results: The levels of MDR1, BCRP, MRP1, Bcl-2/Bax and miR-21 in MCF-7/PR and SKBR-3/PR cells were significantly higher than those in MCF-7 and SKBR-3 cells. The protein levels of P-gp, Bcl-2 were up- regulated, and Bax was down-regulated compared with parental cells. MiR-21 was significantly down-regulated after miR-21 inhibitor was transfected; and the levels of MDR1, BCRP, MRP1 and Bcl-2/Bax (P 〈 0.05) were also down-regulated. MiR-21 inhibitors significantly suppressed G0/G1 transition of the cell cycle, and induced cell apoptosis in MCF-7/PR and SKBR-3/PR ceils. MTF results showed that miR-21 inhibitors induced sensitivity of MCF-7/PR and SKBR-3/PR cells to paclitaxel. And miR-21 mimic can increase the expression of MDR1, Bcl-2/Bax and change cell morphology from parental ceils to resistant cells. Results: The established MCF-7/PR and SKBR-3/PR breast cancer cells show typical muhidrug resistance characteristics, which can be used as the model for drug resistance study. Down-regulated miR-21 expression in MCF-7/PR and SKBR-3/PR breast cancer cells can enhance cell sensitivity to paclitaxel.
出处 《浙江大学学报(医学版)》 CAS CSCD 北大核心 2015年第4期400-409,共10页 Journal of Zhejiang University(Medical Sciences)
基金 国家自然科学基金(81071848) 安徽省自然科学基金(1508085MH159) 安徽省教育厅自然科学重点研究项目(KJ2013A184,KJ2010A240) 国家级大学生创新项目(201310367014)
关键词 乳腺肿瘤 紫杉醇/投药和剂量 微RNAS 抗药性 肿瘤 Breast neoplasms Paclitaxel/administration & dosage MicroRNAs Drug resistance, neoplasm
  • 相关文献

参考文献20

  • 1COCHRANE D R, CIq'I'ELLY D M, HOWE E N, et al. MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer [ J ]. Horm Cancer, 2010,1 (6) :306-319.
  • 2YOSHIMOTO N, TOYAMA T, TAKAHASHI S, et al. Distinct expressions of microRNAs that directly target estrogen receptor alpha in human breast cancer [ J ] Breast Cancer Res Treat, 2011,130( 1 ) :331-339.
  • 3NGEK,WONG C L,MA E S,et al. MicroRNAs as new players for diagnosis, prognosis, and therapeutic targets in breast cancer [ J ]. J Oncol, 2009,2009 : 305 -420.
  • 4IORIO M V, FERRACIN M, LIU C G, et al. MieroRNA gene expression deregulation in human breast caneer[ J ]. Cancer Res, 2005,65 (16) :7065- 7070.
  • 5SARKADI B, OZVEGY-LACZKA C, NEMET K, et al. ABCG2-a transporter for all seasons [ J ]. FEBS Lett, 20O4,567 ( 1 ) : 116-120.
  • 6BARTEL D P. MicroRNAs : genomics, biogenesis, mechanism, and function [J]. Cell, 2004,116(2):281-297.
  • 7ALBINSSON S, SUAREZ Y, SKOURA A, et al. MicroRNAs are necessary for vascular smooth muscle growth, differentiation, and function[J]. Arterioscler Thromb Vase Biol, 2010,30 (6) : 1118-1126.
  • 8WAHID F, SHEHZAD A, KHAN T, et al. MicroRNAs : synthesis, mechanism, function, and recent clinical trims [ J ]. Biochim Biophys Acta, 2010,1803 ( 11 ) :1231-1243.
  • 9NOHATA N, HANAZAWA T, KINOSHITA T, et al. MicmRNAs function as tumor suppressors or oncogenes: aberrant expression of microRNAs in head and neck squamous cell carcinoma [ J ]. Auris Nasus Larynx, 2013,40(2) :143-149.
  • 10TIE J, FAN D. Big roles of microRNAs in tumorigenesis and tumor development [ J ]. Histol Histopathol, 2011,26 (10) : 1353-1361.

二级参考文献68

  • 1汤涛 缪泽鸿 丁健 胥彬 许建华.沙尔威辛抗多药耐药和诱导K562/A02多药耐药细胞凋亡[A].胥彬,许建华.抗癌药物与肿瘤化学治疗进展[C].北京:科学出版社,2001.193—203.
  • 2Chen C Z, Li L, Lodish H F, et al. MiRNA modulate hemato poietic lineage differentiation[J]. Science,2004, 303(5654): 83- 86.
  • 3Bartel D P. MiRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281- 297.
  • 4Blower P E, Chung J H, Verduai J S, et al. MiRNAs modulate the chemosensitivity of tumor cells[J]. Mol Cancer Ther, 2008, 7(1) :1-9.
  • 5Pascal S,Charles D. Chemoresistance in non small cell lung cancer[J]. Curr MedChem, 2005, 5(1):73-88.
  • 6Stewart D J. Mechanisms of resistance to cisplatin and carboplatin[J]. Crit RevOncol Hematol, 2007,63(1):12- 31.
  • 7H Zhu, H Wu, X P Liu, et al. Role of MiRNA miR 27a and miR-451 in the regulation of MDR1/P glycoprotein expression in human cancer cells[J]. Biochemical Pharmacology, 2008, 76 (5) : 582-588.
  • 8Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells[J]. Int J Cancer, 2008, 123(2): 372-379.
  • 9Kovalchuk O, Filkowski J, Meservv J, et al. Involvement of miR NA-451 in resistance of the MCF7 breast cancer ceils to chemothera peutic drug doxorubicin[J]. Mol Cancer Ther, 2008, 7 (7):2152- 2159.
  • 10Meng F, Henson R, Lang M, et al. Involvement of human mi RNA in growth and response to chemotherapy in human cholan giocarcinoma cell lines[J]. Gastroenterology, 2006, 130 (7):2113-2129.

共引文献34

同被引文献83

  • 1阎蓓,邸石,王罡,张婧.香菇多糖对顺铂抑制Hela宫颈癌细胞增殖作用的影响[J].中国生化药物杂志,2014,34(1):49-50. 被引量:3
  • 2王锡林,生梦飞,曲震.紫杉醇和卡铂方案治疗中晚期乳腺癌的临床疗效[J].中国肿瘤临床与康复,2005,12(2):171-173. 被引量:4
  • 3Suzuki S,Sakurai K,Adachi K,et al.Examination of the response rate of paclitaxel and bevacizumab therapy for metastatic advanced breast cancer according to the lymphopenia grade[J].Gan To Kagaku Ryoho,2015,42(10):1249-1251.
  • 4Llombart-Cussac A,Bermejo B,Villanueva C,et al.SOLTI NeoP ARP:a phaseⅡrandomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triplenegative breast cancer[J].Breast Cancer Res Treat,2015,154(2):351-357.
  • 5Shirai K, Tamaki Y, Kitamoto Y, et al. Prognosis was not de- teriorated by multiple primary cancers in esophageal cancer patients treated by radiotherapy[J]. J Radiat Res, 2013, 54 (4): 706-711.
  • 6Tomimaru Y, Eguchi H, Nagano H, et al. Circulating mi- croRNA-21 as a novel biomarker for hepatocellular carcino- ma[J]. J Hepatol, 2012, 56(1):167-175.
  • 7Hari DM, Leung AM, Lee JH. et al. AJCC cancer staging manual 7th edition criteria for colon cancer: Do the com- plex modifications improve prognostic assessment?[J]. J Am Coil Surg, 2013, 217(2): 181-190.
  • 8Atsumi K, Shioyama Y, Arimura H, et al. Esophageal steno- sis associated with tumor regression in radiotherapy for esophageal cancer: frequency Oncol Biol Phys, 2012, 82(5) and prediction[J]. Int J Radiat 1973-1980.
  • 9Nomura M, Shitara K, Kodaira T, et al. Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy[J]. Int J Radiat Oncol Biol Phys, 2012, 82(2): 946-952.
  • 10Swisher SG, Winter KA, Komaki RU, et al. A phase II study of a paclitaxel-based chemoradiation regimen with se- lective surgical salvage for resectable locoregionally ad- vanced esophageal cancer: Initial reporting of RTOG 0246 [J]. lnt J Radiat Oncol Biol Phys, 2012, 82(5): 1967-1972.

引证文献12

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部